The data in this manuscript suggests that the addition of fimepinostat to the upfront chemotherapy regime for the treatment of SCLC could improve outcomes and that whilst patients should not necessarily be stratified based on MYC expression those patients with MYC amplification are likely to achieve the benefit of the ability of fimepinostat to reduce MYC expression and prolong platinum response. Here, MYC is linked to small cell lung carcinoma.